We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02094586
Recruitment Status : Completed
First Posted : March 24, 2014
Last Update Posted : July 16, 2015
Information provided by (Responsible Party):
PaxVax, Inc.

Brief Summary:
The primary goal of this Phase III study is to compare 3 lots for consistency of manufacture.

Condition or disease Intervention/treatment Phase
Cholera Biological: PXVX0200 Biological: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR
Study Start Date : May 2014
Primary Completion Date : February 2015
Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cholera
U.S. FDA Resources

Arm Intervention/treatment
Experimental: PXVX0200
PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x108 CFU in a liquid suspension
Biological: PXVX0200
comparing 3 lots of PXVX0200
Placebo Comparator: Placebo
Placebo physiological saline
Biological: Placebo

Primary Outcome Measures :
  1. The geometric mean antibody titer (GMT) of each lot must be within ± 50% of each other lot with 95% confidence. [ Time Frame: Measured 10 days following vaccination ]

Secondary Outcome Measures :
  1. Percentage of vaccinees with at least a 4-fold rise vibriocidal antibody [ Time Frame: Measured 10 days after vaccination ]
  2. tolerability of vaccine [ Time Frame: following vaccination through 180 days ]
    Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever Incidence and severity of unsolicited adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy men or women,
  • age 18 to 45 years inclusive;
  • normal medical history and physical examination
  • Women must have a negative pregnancy test.

Exclusion Criteria:

  • travel to a cholera endemic area in the previous 5 years;
  • abnormal stool pattern or regular use of laxatives;
  • Currently active unstable or undiagnosed medical conditions
  • current or recent antibiotic use;
  • pregnancy or nursing;
  • Previously received a licensed or investigational cholera vaccine
  • History of cholera or enterotoxigenic E. coli infection
  • History of Guillain-Barré Syndrome
  • Received or plans to receive any other licensed vaccines, except for seasonal influenza
  • Recipient of bone marrow or solid organ transplant
  • Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years
  • Use of systemic chemotherapy in the previous 5 years prior to the study
  • any immunosuppressive medical condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02094586

  Show 25 Study Locations
Sponsors and Collaborators
PaxVax, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: PaxVax, Inc.
ClinicalTrials.gov Identifier: NCT02094586     History of Changes
Other Study ID Numbers: PXVX-VC-200-004
First Posted: March 24, 2014    Key Record Dates
Last Update Posted: July 16, 2015
Last Verified: July 2015

Additional relevant MeSH terms:
Vibrio Infections
Gram-Negative Bacterial Infections
Bacterial Infections